Terumo Corporation, a Japanese medical equipment manufacturer, has introduced a new corporate venture capital (CVC) fund named "Terumo Ventures." Managed as a department within Terumo Americas Holding, Inc., this fund will concentrate on advancing the group's venture investments. With an allocation of $75 million, the fund will invest in healthcare technologies. Through these strategic investments, Terumo seeks to explore potential mergers and acquisitions, enhancing its position in the healthcare sector.
Terumo Ventures will be active in major global innovation hubs, such as Massachusetts and California, as well as in the United States and Belgium. Over the next five years, the fund intends to invest in early-stage companies specializing in cardiovascular disease treatment, chronic disease management, and digital technologies. This initiative is designed to improve Terumo’s access to groundbreaking technologies and innovative business ideas from startups, fostering open innovation and complementing its internal R&D activities.
Since 2013, Terumo has been cultivating relationships with medtech startups by investing in venture capital funds in the U.S. and China. The establishment of Terumo Ventures will allow the company to be more agile in identifying and executing venture investments, accelerating its ability to acquire technologies and develop a strong pipeline for future mergers and acquisitions. Terumo has included the launch of this CVC in its 5-Year Growth Strategy, “GS26”, and its long-term vision of transitioning “From Devices to Solutions”. By focusing on solutions to address various medical challenges and unmet needs, Terumo aims to expand its foothold in the healthcare industry.
Terumo has also created a new director position to oversee innovation-related functions throughout the company. Established in April 2024, this role will centrally manage research and development, intellectual property, clinical development, digital transformation, and venture investments. The aim is to enhance cross-functional collaboration and streamline the company’s innovation processes.
Terumo plans to expand its innovation capabilities through a combination of internal development and strategic partnerships with external entities. This approach will enable the company to continue providing valuable medical solutions and address evolving healthcare needs, ultimately benefiting patients, medical professionals, and society as a whole.
With a century-long legacy in the medical technology industry, Terumo remains committed to its mission of "Contributing to Society through Healthcare". Headquartered in Tokyo, the company operates globally with more than 30,000 employees and provides a diverse range of medical products and services across over 160 countries. Terumo continues to play a crucial role in advancing healthcare worldwide, offering solutions in vascular interventions, cardio-surgical care, blood transfusion systems, and diabetes management.